Collaborative Referral Model to Achieve Hepatitis C Micro-Elimination in Methadone Maintenance Treatment Patients during the COVID-19 Pandemic

Although hepatitis C virus (HCV) prevails in patients receiving methadone maintenance treatment (MMT), most do not receive anti-HCV therapy. This single-center observational study aimed to achieve HCV micro-elimination at an MMT center during the COVID-19 pandemic using a collaborative referral model, which comprised a referral-for-diagnosis stage (January 2020 to August 2020) and an on-site-diagnosis stage (September 2020 to January 2021). A multidisciplinary team was established and all MMT center patients were enrolled. HCV micro-elimination was defined as >90% of HCV-infected patients diagnosed and >80% of HCV-viremic patients treated. A total of 305 MMT patients, including 275 (90.2%) anti-HCV seropositive patients, were enrolled. Among 189 HCV-infected patients needing referral, the accumulative percentage receiving HCV RNA testing increased from 93 (49.2%) at referral-for-diagnosis stage to 168 (88.9%) at on-site-diagnosis stage. Among 138 HCV-viremic patients, the accumulative percentage receiving direct-acting antiviral (DAA) therapy increased from 77 (55.8%) at referral-for-diagnosis stage to 129 (93.5%) at on-site-diagnosis stage. We achieved an HCV RNA testing rate of 92.4% (254/275), an HCV treatment rate of 95.8% (203/212) and a sustained virological response rate of 94.1% (191/203). The collaborative referral model is highly effective in HCV RNA testing and HCV treatment uptake among MMT patients, achieving HCV micro-elimination.

[1]  V. Di Marco,et al.  Hepatitis C: Standard of Treatment and What to Do for Global Elimination , 2022, Viruses.

[2]  Jisoo A. Kwon,et al.  Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. , 2022, The lancet. Gastroenterology & hepatology.

[3]  S. Alavian,et al.  An on-site community-based model for hepatitis C screening, diagnosis, and treatment among people who inject drugs in Kerman, Iran: The Rostam study. , 2022, The International journal on drug policy.

[4]  T. Antoniou,et al.  Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis , 2021, Viruses.

[5]  P. Easterbrook,et al.  Outcomes of the CT2 study: A ‘one‐stop‐shop’ for community‐based hepatitis C testing and treatment in Yangon, Myanmar , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[6]  Y. Shih,et al.  Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan , 2021, Scientific Reports.

[7]  P. Hayes,et al.  REDUCTION IN THE POPULATION PREVALENCE OF HCV VIRAEMIA AMONG PEOPLE WHO INJECT DRUGS ASSOCIATED WITH SCALE-UP OF DIRECT-ACTING ANTIVIRAL THERAPY IN COMMUNITY DRUG SERVICES: REAL WORLD DATA. , 2021, Addiction.

[8]  Ming‐Lung Yu,et al.  Scaling up the in-hospital hepatitis C virus care cascade in Taiwan , 2020, Clinical and molecular hepatology.

[9]  P. Read,et al.  Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs: A systematic review and meta-analysis. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Ding‐Shinn Chen,et al.  Taiwan is on track of accelerating hepatitis C elimination by 2025 , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[11]  L. Abu-Raddad,et al.  The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa , 2020, Addiction.

[12]  M. Mondelli,et al.  Elimination of hepatitis C in Europe: can WHO targets be achieved? , 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[13]  N. Luhmann,et al.  We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade , 2019, Journal of internal medicine.

[14]  C. Tai,et al.  Integrated care for methadone maintenance patients with hepatitis C virus infection , 2019, The Kaohsiung journal of medical sciences.

[15]  Josephine G. Walker,et al.  The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. , 2019, The lancet. Gastroenterology & hepatology.

[16]  J. Leung,et al.  Global, regional, and country‐level estimates of hepatitis C infection among people who have recently injected drugs , 2018, Addiction.

[17]  G. Dore,et al.  Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. , 2018, The lancet. Gastroenterology & hepatology.

[18]  T. Tseng,et al.  Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection , 2018, Alimentary pharmacology & therapeutics.

[19]  P. Read,et al.  Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. , 2018, The lancet. Gastroenterology & hepatology.

[20]  S. Basu,et al.  Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study. , 2017, The Lancet. Infectious diseases.

[21]  J. Leung,et al.  Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review , 2017, The Lancet. Global health.

[22]  J. Montaner,et al.  High prevalence of willingness to use direct‐acting antiviral‐based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs , 2017, HIV medicine.

[23]  G. Dore,et al.  Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review. , 2017, The International journal on drug policy.

[24]  D. Nelson,et al.  Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. , 2017, Annals of internal medicine.

[25]  Gamal Esmat,et al.  Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.

[26]  Ming‐Lung Yu,et al.  Hepatitis C Virus Infection among Injection Drug Users with and without Human Immunodeficiency Virus Co-Infection , 2014, PloS one.

[27]  J. McVeigh,et al.  Views and experiences of hepatitis C testing and diagnosis among people who inject drugs: systematic review of qualitative research. , 2014, The International journal on drug policy.